Connection
Mark Boguniewicz to Clinical Trials, Phase III as Topic
This is a "connection" page, showing publications Mark Boguniewicz has written about Clinical Trials, Phase III as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.102 |
|
|
|
-
Beck LA, Muraro A, Boguniewicz M, Chen Z, Zahn J, RodrÃguez Marco A. Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2025 Jan; 155(1):135-143.
Score: 0.055
-
Blauvelt A, Boguniewicz M, Brunner PM, Luna PC, Biswas P, DiBonaventura M, Farooqui SA, Rojo R, Cameron MC. Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life. J Dermatolog Treat. 2022 Aug; 33(5):2605-2613.
Score: 0.047